Table 3.
Response Data
| Response | Treatment Strata |
|||||||
|---|---|---|---|---|---|---|---|---|
| Platinum Sensitive (n = 80) |
Platinum Refractory (n = 99) |
|||||||
| Arm A: Ziv-Aflibercept + Topotecan (n = 41) |
Arm B: Topotecan (n = 39) |
Arm A: Ziv-Aflibercept + Topotecan (n = 51) |
Arm B: Topotecan (n = 48) |
|||||
| No. | % | No. | % | No. | % | No. | % | |
| CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR* | 1 | 2 | 0 | 0 | 1 | 2 | 0 | 0 |
| SD | 14 | 34 | 7 | 18 | 12 | 24 | 7 | 15 |
| DCR† | 15 | 37 | 7 | 18 | 13 | 25 | 7 | 15 |
| Progressive disease | 18 | 44 | 29 | 74 | 29 | 57 | 33 | 69 |
| Symptomatic deterioration | 3 | 7 | 1 | 3 | 2 | 4 | 3 | 6 |
| Early death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Assessment inadequate | 5 | 12 | 2 | 5 | 7 | 14 | 4 | 8 |
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; DCR, disease control rate.
Both partial responses were unconfirmed.
DCR = CR + PR + SD.